# ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer

> **NCT00350051** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 53 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Sagopilone (ZK 219477) + prednisone

## Key facts

- **NCT ID:** NCT00350051
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-01
- **Primary completion:** 2008-09-24
- **Final completion:** 2009-12-21
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00350051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00350051, "ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00350051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*